Sysmex Europe and GLP Systems to attend Euromedlab
GLP Systems and Sysmex are delighted to be attending the Euromedlab fair and conference in Milan together - one of Europe’s leading platforms for clinical chemistry and laboratory medicine. With a real-life demonstration of the new track system, GLP Systems is looking forward to providing details about the new concept. One of the first solutions will be GLP’s superb island storage solution – available track-linked or as an island solution. It is fully automated and capable of storing up to 10,000 samples. The track is expected to steal the show, however, with its intelligent cars that transport individual samples dynamically to and from the various analysers and other devices.
One of the main changes is that lab owners can now choose a system that delivers complete independence from analyser manufacturers. This freedom of choice leads to full cost manageability. The system is also significantly faster than current solutions. Manageability and independence are further underlined by the fact that the system is entirely modular. It can be expanded as needed - from storage units only to total lab automation. This can cover all chemistries and sample volumes. Investments are secure for many years to come.
Both Sysmex and GLP Systems are passionate about using knowledge and experience to provide tangible, reliable solutions – for both existing and projected issues. The success in their approach lies in reducing complexity to a minimum, eliminating the traditionally weak links in the automation process and so creating new possibilities.
Despite the close operational cooperation, both companies continue to operate as independent entities.
Sysmex is a global group, with more than 40 overseas subsidiaries conducting business in more than 170 countries. It develops, produces and sells instruments, reagents and software used in in-vitro diagnostics in hospitals and testing centres. In the global market, Sysmex ranks in the top 10 in diagnostics. In haematology, it holds the top share of the global market.
Overseas business development has been a focus for Sysmex since it was founded. It operates R&D, production, sales and customer support facilities around the world to ensure products and services are delivered that meet the needs of the customer in each region. Principal clinical areas of activity are: haematology, haemostasis, immunochemistry, urinalysis, clinical chemistry and life science. For more information please visit http://www.sysmex-europe.com
About GLP Systems
Located in Hamburg, Germany, GLP Systems is driven by the desire to eliminate the traditional limitations in lab automation. It is doing so by applying three basic principles: freedom, excellence and simplicity. The resulting solutions deliver superb levels of performance, choice and total manageability. The company draws on the experience, know-how and strength of its founders and shareholders, Dr. André von Froreich, Dr. Robert Hecht and Sonic Healthcare Germany.
Sysmex Europe GmbH
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Sysmex Europe and GLP Systems to attend Euromedlab here
News-ID: 261346 • Views: …
More Releases from Sysmex Europe GmbH
Sysmex Medical Scientific Department Presentations at Euromedlab 2013
Norderstedt, Germany, 28 May 2013 - The Sysmex Europe Medical Scientific Department gave four exciting presentations at Euromedlab in Milan last week. They were attended by over 500 people across two sessions. The presentations addressed the latest findings in laboratory diagnostics developed in cooperation with Sysmex’s R&D and Clinical Management Concepts departments in Kobe, Japan. Those attending included prime decision-makers from laboratories across Europe and the world looking to improve
More Releases for GLP
GLP Analogs Market Report, History and Forecast 2020-2026|Novo Nordisk, AstraZen …
" Los Angeles, United States – – QY Research offers an overarching research and analysis-based study on the global GLP Analogs market, covering growth prospects, market development potential, profitability, supply and demand, and other important subjects. The report presented here comes out as a highly reliable source of information and data on the global GLP Analogs market. The researchers and analysts who have prepared the report used an advanced research methodology
Glucagon Like Peptide-1 (GLP-1) Agonists Market - key players covered:GSK, Sanof …
Los Angeles, United State, –The report titled Global Glucagon Like Peptide-1 (GLP-1) Agonists Market is one of the most comprehensive and important additions to QY Research’s archive of market research studies. It offers detailed research and analysis of key aspects of the global Glucagon Like Peptide-1 (GLP-1) Agonists market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer
In safe hands with the GLP checklist
The "Good Laboratory Practice" regulatory mandate (GLP for short) was introduced in 1978 after the FDA (U.S. Food and Drug Administration) had already identified significant deficiencies in toxicological studies in the years preceding. The German Chemicals Act was introduced in an effort to ensure that newly approved drugs for human consumption really are safe and minimize any and all risks. The values of transparency, traceability, assignment of responsibilities, and safekeeping are
Glucagon-Like Peptide-1 (Glp-1) Analogs Market | Global Opportunity Analysis, 20 …
Glucagon-like peptide-1 (GLP-1) analogs also known as incretin mimetics are class of drugs indicated for type-2 diabetes mellitus to lower the blood sugar level. GLP-1 analogs prevents the breakdown of GLP-1, thereby enhancing the glucose depended insulin release, suppresses the glucagon release (which reduces hepatic glucose output), and reduces gastric emptying rate (resulting in weight loss from reduced appetite). GLP-1 analogs do not cause hypoglycemia like other class of anti-diabetic
The Global Report Focuses on Glucagon Like Peptide-1 (GLP-1) Agonists Market 201 …
"The Report Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz" The Global Glucagon Like Peptide-1 (GLP-1) Agonists Market 2016 Research Report is a professional and in-depth study on the current state of the Glucagon like peptide-1 (GLP-1) agonists industry. The report provides a basic overview of the industry including definitions, classifications, applications and
Pharmacelsus' GLP implementation exemplary for European CROs
Scientists of the European Center for Validation of Alternative Methods (ECVAM) attended a GLP workshop at Pharmacelsus GmbH Saarbrücken, 4. Juni 2009 - Pharmacelsus, a CRO specialized in preclinical test services, obtained GLP-certification covering the complete portfolio in November 2008. The company is not only able to perform accompanying analytical services for clinical studies in addition to its preclinical services, but also decided to share its knowledge on the GLP